December 7, 2004
AMERIPATH, INC. ACQUISITION OF PATHOLOGY ASSOCIATES IN NEW YORK

FOR IMMEDIATE RELEASE

Contact: David L. Redmond, Executive Vice President & CFO
561-712-6226
dredmond@ameripath.com

Riviera Beach, FL, December 7, 2004 – AmeriPath, Inc., a leading national provider of cancer diagnostics, genomics, and related information services, today announced the acquisition of Pathology Associates, P.C. Pathology Associates, headquartered in New Rochelle, New York, is one of the largest and most well respected Dermatopathology practices in the greater New York metropolitan area. The area serviced by Pathology Associates is approximately a seventy-five mile radius around their New Rochelle location capturing densely populated areas of New York, New Jersey, and Connecticut.

Don Steen, Chairman and CEO of AmeriPath stated “We are very pleased that Pathology Associates has joined AmeriPath. Dr. Halperin and his colleagues have a long history of providing high quality Dermatopathology services to their clients in the region. As partners, we believe that we will be able to provide the additional resources necessary to expand the physicians’ geographic coverage and the breadth of Dermatopathology services they offer.”

Alan Halperin, M.D., Managing Director and founder of Pathology Associates added “We are excited about joining AmeriPath and look forward to working with a leading provider of Dermatopathology services. In addition to sharing our passion for providing the highest quality Dermatopathology services to clients and their patients, AmeriPath values the contributions of their many skilled board certified Dermatopathologists in teaching within Dermatopathology, Dermatology, and related fields. These attributes have also been the pillars of Pathology Associates’ success.”

AmeriPath is a leading national provider of cancer diagnostics, genomics, and related information services. AmeriPath’s extensive diagnostics infrastructure includes the Center for Advanced Diagnostics (CAD), a division of AmeriPath. CAD provides specialized diagnostic testing and information services including Fluorescence In-Situ Hybridization (FISH), Flow Cytometry, DNA Analysis, Polymerase Chain Reaction (PCR), Molecular Genetics, Cytogenetics and HPV Typing. Additionally, AmeriPath provides clinical trial and research development support to firms involved in developing new cancer and genomic diagnostics and therapeutics.

Additional information regarding the acquisition will be provided by AmeriPath on a Form 8-K in accordance with SEC requirements and can be found on the SEC’s website at www.sec.gov.

......................................................................................................................................................

The above statements include forward-looking statements based on current management expectations. Such statements are sometimes identified by words such as "may," "should," "believe," "expect," "anticipate," "estimate," "project" and similar expressions and may include financial or operating estimates, forecasts or projections. Numerous factors exist which may cause results to differ materially from these expectations. Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict and these forward-looking statements are subject to risks and uncertainties relating to the Company, including without limitation (i) possible changes in reimbursement rates under government and third party healthcare programs and the payments received under such programs, (ii) the Company's ability to attract, motivate and retain pathologists and senior management, (iii) risks associated with the Company's acquisition strategies, including without limitation the successful completion and integration of acquisitions (and achievement of planned or expected synergies) and the availability of pathology practices in appropriate locations that the Company is able to acquire on suitable terms or develop, (iv) federal and state healthcare regulation (and compliance), (v) changes in coding, (vi) the highly competitive nature of the healthcare business, and (vii) those risks and uncertainties detailed from time to time in the Company's filings with the SEC. Therefore, the Company's actual results may differ materially. The Company undertakes no obligation to update any forward-looking statements or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.